Comparison of hyper-fractionated accelerated and standard fractionated radiotherapy with concomitant low-dose gemcitabine for unresectable pancreatic cancer

Anticancer Research

Volumn 28, Issue 4 C, 2008, Pages 2369-2372

  Maemura, Kosei ^a   Shinchi, Hiroyuki ^a   Noma, Hidetoshi ^a   Mataki, Yuko ^a   Kurahara, Hiroshi ^a   Maeda, Shinichi ^a   Hiraki, Yoshiyuki ^a   Nakajo, Masayuki ^a   Natsugoe, Shoji ^a   Takao, Sonshin ^b  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Chemoradiotherapy; Conformal radiotherapy; Gemcitabine; Hyper fractionated accelerated radiotherapy; Pancreas; Unresectable cancer

Indexed keywords

GEMCITABINE;

ADULT; ANOREXIA; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED RADIOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG FATALITY; FEMALE; FOLLOW UP; HUMAN; INOPERABLE CANCER; LOW DRUG DOSE; MALE; NAUSEA AND VOMITING; NEUTROPENIA; PANCREAS CANCER; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; THROMBOCYTOPENIA; TOTAL PARENTERAL NUTRITION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIMETABOLITES, ANTINEOPLASTIC; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DOSE FRACTIONATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY, CONFORMAL;

EID: 48849112730     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. DiMagno EP, Reber HA and Tempero MA: AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology 117: 1464-1484, 1999.
2. Schnall SF and Macdonald JS: Chemotherapy of adenocarcinoma of the pancreas. Semin Oncol 23: 220-228, 1996.
3. Gastrointestinal Tumor Study Group: Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 80: 751-755, 1988.
4. Micke O, Hesselmann S, Bruns F et al: Results and follow-up of locally advanced cancer of the exocrine pancreas treated with radiochemotherapy. Anticancer Res 25: 1523-1530, 2005.
5. Ikeda M, Okada S, Tokuuye K et al: A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Br J Cancer 86: 1551-1554, 2002.
6. Shinchi H, Takao S, Noma H et al: Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 53: 146-150, 2002.
7. Lawrence TS, Eisbruch A and Shewach DS: Gemcitabine-mediated radiosensitization. Semin Oncol 24(Suppl 7): 24-28, 1997.
8. Flanagan SA, Robinson BW, Krokosky CM et al: Mismatched nucleotides as the lesions responsible for radiosensitization with gemcitabine: a new paradigm for antimetabolite radiosensitizers. Mol Cancer Ther 6: 1858-1868, 2007.
9. Wendt CD, Peters LJ, Ang KK et al: Hyperfractionated radiotherapy in the treatment of squamous cell carcinomas of the supraglottic larynx. Int J Radiat Oncol Biol Phys 17: 1057-1062, 1989.
10. Zwitter M, Kovac V, Smrdel U et al: Gemcitabine, cisplatin, and hyperfractionated accelerated radiotherapy for locally advanced non-small cell lung cancer. J Thorac Oncol 1: 662-666, 2006.
11. Milano MT, Haraf DJ, Stenson KM et al: Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck. Clin Cancer Res 10: 4922-4932, 2004.
12. Crane CH, Abbruzzese JL, Evans DB et al: Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys 52: 1293-1302, 2002.
13. Wolff RA, Evans DB, Gravel DM et al: Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res 7: 2246-2253, 2001.
14. Blackstock AW, Bernard SA, Richards F et al: Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol 17: 2208-2212, 1999.
15. Joensuu TK, Kiviluoto T, Kärkkäinen P et al: Phase I-II trial of twice-weekly gemcitabine and concomitant irradiation in patients undergoing pancreaticoduodenectomy with extended lymphadenectomy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 60: 444-452, 2004.
16. Prott FJ, Schönekaes K, Preusser P et al: Combined modality treatment with accelerated radiotherapy and chemotherapy in patients with locally advanced inoperable carcinoma of the pancreas: results of a feasibility study. Br J Cancer 75: 597-601, 1997.
17. Bourhis J, Overgaard J, Audry H et al: Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 368: 843-854, 2006.
18. Saunders M, Dische S, Barrett A et al: Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: a randomised multicentre trial. Lancet 350: 161-165, 1997.
19. Seydel HG, Stablein DM, Leichman LP et al: Hyperfractionated radiation and chemotherapy for unresectable localized adenocarcinoma of the pancreas. The Gastrointestinal Tumor Study Group experience. Cancer 65: 1478-1482, 1990.